Unlocking the Therapeutic Potential of Neuroplastogens

Neuroplastogens are  the Next Big Therapeutic Opportunity

Compelling preclinical evidence of enhanced neuroplasticity and cellular resilience support development across a diverse range of indications - from neuropsychiatry to ophthalmology.

Opportunity is an order of magnitude larger than first-generation psychedelic drug candidates because these therapies can be secured, scaled, and rapidly developed through human proof-of- concept trials.

Negev Labs Drives Value Creation

A Disciplined and Efficient Approach to Company Building

Source, validate and secure valuable IP

Build disease-focused biopharma companies

Rapidly advance to human proof-of-concept trial

Maximize returns via strategic exits

Our value proposition lies in its proactive and efficient approach to company building.

We transcend the limitations of traditional incubators and accelerators by directly acquiring or licensing promising intellectual property (IP) and building laser-focused, capital-efficient proto-companies. 

These proto-companies are strategically designed to rapidly de-risk assets and achieve significant value inflection points.

Management Team

Ken Belotsky

Managing Partner

Partner at Negev Capital since 2021. 
15 years managing startups. Co-founder of Bright Box acquired by Zurich Insurance in 2018. Co-founder of BrightConsult acquired by Incadea in 2011.

Kostia Adamsky

Partner, Chief Operating Officer

Principal at Negev Capital . VP Ops at Levco Pharmaceuticals Ltd, CEO & VP Ops at Regenera Pharma LTD., Director and co-CEO at Targia Pharmaceuticals. PhD in cell biology from Weizmann Institute.

Heresh Rezavandi

Partner, Strategy & Pharma Partnering

14+ years' experience in life science R&D, portfolio, search and evaluation, BD&L, marketing, strategy in global roles at UCB, Bayer, Roche and Angelini. PhD in Biochemistry.

Shlomi Raz

Partner

President & CBO of Beckley Psytech and Founder & CEO of Eleusis Therapeutics. Managing Director at Goldman Sachs. MA from NYU and BS from Georgetown University.

Bernard Lerer, MD, PhD

Science Partner

Professor of Psychiatry at Hadassah-Hebrew University Medical Center and the founder at Hadassah BrainLabs Institute.

C. Anthony Altar

Head of Scientific Advisory Board

40+ years' experience in biotech & psychiatric drug discovery, leader at Genentech, Regeneron, and Otsuka. President & COO at Splice Therapeutics.

Contact us

Thank you for getting in touch!

We appreciate you contacting us. One of our colleagues will get back in touch with you soon!

Have a great day!

Oops! Something went wrong while submitting the form.

Unlocking the Therapeutic Potential of Neuroplastogens

Neuroplastogens are  the Next Big Therapeutic Opportunity

Compelling preclinical evidence of enhanced neuroplasticity and cellular resilience support development across a diverse range of indications - from neuropsychiatry to ophthalmology.

Opportunity is an order of magnitude larger than first-generation psychedelic drug candidates because these therapies can be secured, scaled, and rapidly developed through human proof-of- concept trials.

Negev Labs Drives Value Creation

A Disciplined and Efficient Approach to Company Building

Source, validate and secure valuable IP

Build disease-focused biopharma companies

Rapidly advance to human proof-of-concept trial

Maximize returns via strategic exits

Management Team

Ken Belotsky

Managing Partner

Kostia Adamsky

Partner, Chief Operating Officer

Heresh Rezavandi

Partner, Strategy & Pharma Partnering

Shlomi Raz

Partner

Bernard Lerer, MD, PhD

Science Partner

C. Anthony Altar

Head of Scientific Advisory Board

News & Announcements

Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs

Negev Labs Emerges from Stealth with Announcement of Alexander Shulgin Research Institute Licensing...

Negev debuts with company creation engine centred around next-gen psychedelics

Contact us

Thank you for getting in touch!

Unlocking the Therapeutic Potential of Neuroplastogens

Neuroplastogens are the Next Big Therapeutic Opportunity

Compelling preclinical evidence of enhanced neuroplasticity and cellular resilience support development across a diverse range of indications - from neuropsychiatry to ophthalmology.

Opportunity is an order of magnitude larger than first-generation psychedelic drug candidates because these therapies can be secured, scaled, and rapidly developed through human proof-of- concept trials.

Negev Labs Drives Value Creation

A Disciplined and Efficient Approach to Company Building

Source, validate and secure valuable IP

Build disease-focused biopharma companies

Rapidly advance to human proof-of-concept trial

Maximize returns via strategic exits

Management Team

Ken Belotsky

Managing Partner

Kostia Adamsky

Partner, Chief Operating Officer

Heresh Rezavandi

Partner, Strategy & Pharma Partnering

Shlomi Raz

Partner

Bernard Lerer, MD, PhD

Science Partner

C. Anthony Altar

Head of Scientific Advisory Board

News & Announcements

Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs

Negev Labs Emerges from Stealth with Announcement of Alexander Shulgin Research Institute Licensing...

Negev debuts with company creation engine centred around next-gen psychedelics

Contact us

Thank you for getting in touch!

Neuroplastogens are  the Next Big Therapeutic Opportunity

A Disciplined and Efficient Approach to Company Building